Reduced neutralizing antibody response to SARS‐CoV‐2 vaccine booster dose in people living with HIV with severe immunosuppression
The aim of this study was to assess the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) vaccines among people living with HIV (PLWH) with severe immunosuppression, after a booster dose. The design was a case–control study nested in a prospective cohort of PLWH. All pat...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 2023-03, Vol.95 (3), p.e28602-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e28602 |
| container_title | Journal of medical virology |
| container_volume | 95 |
| creator | Corma‐Gómez, Anaïs Fernández‐Fuertes, Marta Viñuela, Laura Domínguez, Carmen Santos, Marta Fuentes‐López, Ana Rojas, Almudena Fernández‐Pérez, Nieves Martín‐Carmona, Jessica Serrano‐Conde, Esther Real, Luis M. Mendoza, Joaquín Macías, Juan Pineda, Juan A. García, Federico |
| description | The aim of this study was to assess the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) vaccines among people living with HIV (PLWH) with severe immunosuppression, after a booster dose. The design was a case–control study nested in a prospective cohort of PLWH. All patients with CD4 cell count |
| doi_str_mv | 10.1002/jmv.28602 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2784387443</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2791909441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3882-7440f2b7dc6e445164c3b75bd2d213320a1aecbf5028fc405c526489370f3bfb3</originalsourceid><addsrcrecordid>eNp10b9u1TAUBnALgeilMPACyBILDGmP_yRxxuoKaFFRpRbuGsXOCfgqsYOd3OoysbDzjH2SuqR0QGKxPfz0nWN9hLxkcMQA-PF22B1xVQB_RFYMqiKroGSPyQqYLLKiYPkBeRbjFgBUxflTciAKpYAVckV-XWI7G2ypw3kKTW9_WPeVNm6y2rd7GjCO3kWkk6dXJ5dXNz9_r_0mnZzuGmOsQ6q9jxMG2vrErKMj-rFH2tvdXdK1nb7R07PN8oi4w5DUMMzOx3kcU3603j0nT7qmj_ji_j4kX96_-7w-zc4vPpytT84zI5TiWSkldFyXrSlQyjx9wAhd5rrlLWdCcGhYg0Z3OXDVGQm5yXkhVSVK6ITutDgkb5bcMfjvM8apHmw02PeNQz_HmpdKCpXGiERf_0O3fg4ubZdUxSqopGRJvV2UCT7GgF09Bjs0YV8zqO-6qVM39Z9ukn11nzjrAdsH-beMBI4XcG173P8_qf74abNE3gJkUJtS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2791909441</pqid></control><display><type>article</type><title>Reduced neutralizing antibody response to SARS‐CoV‐2 vaccine booster dose in people living with HIV with severe immunosuppression</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Corma‐Gómez, Anaïs ; Fernández‐Fuertes, Marta ; Viñuela, Laura ; Domínguez, Carmen ; Santos, Marta ; Fuentes‐López, Ana ; Rojas, Almudena ; Fernández‐Pérez, Nieves ; Martín‐Carmona, Jessica ; Serrano‐Conde, Esther ; Real, Luis M. ; Mendoza, Joaquín ; Macías, Juan ; Pineda, Juan A. ; García, Federico</creator><creatorcontrib>Corma‐Gómez, Anaïs ; Fernández‐Fuertes, Marta ; Viñuela, Laura ; Domínguez, Carmen ; Santos, Marta ; Fuentes‐López, Ana ; Rojas, Almudena ; Fernández‐Pérez, Nieves ; Martín‐Carmona, Jessica ; Serrano‐Conde, Esther ; Real, Luis M. ; Mendoza, Joaquín ; Macías, Juan ; Pineda, Juan A. ; García, Federico</creatorcontrib><description><![CDATA[The aim of this study was to assess the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) vaccines among people living with HIV (PLWH) with severe immunosuppression, after a booster dose. The design was a case–control study nested in a prospective cohort of PLWH. All patients with CD4 cell count <200 cells/mm3 who had received additional dose of messenger RNA (mRNA) COVID‐19 vaccine, after a standard immunization scheme were included. Control group: patients age‐ and sex‐matched, with CD4 ≥ 200 cells/mm3, in the ratio of 2:1. Antibody response to a booster dose (anti‐S levels 33.8 ≥ BAU/mL) and neutralizing activity against SARS‐CoV‐2 B.1, B.1.617.2, and Omicron BA.1, BA.2, and BA.5 strains were assessed after the booster shot. Fifty‐four PLWH were included, 18 with CD4 counts < 200 cells/mm3. Fifty‐one (94%) showed response to a booster dose. Response was less frequent in PLWH with CD4 < 200 cells/mm3 than in those with CD4 counts ≥ 200 cells/mm3 (15 [83%] vs. 36 [100%], p = 0.033). In the multivariate analysis, CD4 counts ≥ 200 cells/mm3 [incidence rate ratio (IRR) = 18.1 (95% confidence interval [CI]: 16.8–19.5), p < 0.001] was associated with a higher probability of showing antibody response. Neutralization activity against SARS‐CoV‐2 B.1, B.1.617, BA.1, and BA.2 strains was significantly inferior among individuals with CD4 counts < 200 cells/mm3. In conclusion, among PLWH with CD4 counts < 200 cells/mm3, the immune response elicited by mRNA additional vaccine dose is reduced.]]></description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.28602</identifier><identifier>PMID: 36880164</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Antibodies ; Antibodies, Neutralizing ; Antibodies, Viral ; Antibody Formation ; Antibody response ; Case-Control Studies ; CD4 antigen ; CD4 T‐cell counts ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 Vaccines ; HIV ; HIV Infections ; Human immunodeficiency virus ; Humans ; Immune response ; Immune system ; Immunization ; Immunogenicity ; Immunosuppression ; Immunosuppression Therapy ; mRNA ; Multivariate analysis ; Neutralization ; Neutralizing ; people living with HIV ; Prospective Studies ; RNA, Messenger ; SARS-CoV-2 ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Sexually transmitted diseases ; Statistical analysis ; STD ; vaccine ; Vaccines ; Virology</subject><ispartof>Journal of medical virology, 2023-03, Vol.95 (3), p.e28602-n/a</ispartof><rights>2023 The Authors. published by Wiley Periodicals LLC.</rights><rights>2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3882-7440f2b7dc6e445164c3b75bd2d213320a1aecbf5028fc405c526489370f3bfb3</citedby><cites>FETCH-LOGICAL-c3882-7440f2b7dc6e445164c3b75bd2d213320a1aecbf5028fc405c526489370f3bfb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.28602$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.28602$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36880164$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Corma‐Gómez, Anaïs</creatorcontrib><creatorcontrib>Fernández‐Fuertes, Marta</creatorcontrib><creatorcontrib>Viñuela, Laura</creatorcontrib><creatorcontrib>Domínguez, Carmen</creatorcontrib><creatorcontrib>Santos, Marta</creatorcontrib><creatorcontrib>Fuentes‐López, Ana</creatorcontrib><creatorcontrib>Rojas, Almudena</creatorcontrib><creatorcontrib>Fernández‐Pérez, Nieves</creatorcontrib><creatorcontrib>Martín‐Carmona, Jessica</creatorcontrib><creatorcontrib>Serrano‐Conde, Esther</creatorcontrib><creatorcontrib>Real, Luis M.</creatorcontrib><creatorcontrib>Mendoza, Joaquín</creatorcontrib><creatorcontrib>Macías, Juan</creatorcontrib><creatorcontrib>Pineda, Juan A.</creatorcontrib><creatorcontrib>García, Federico</creatorcontrib><title>Reduced neutralizing antibody response to SARS‐CoV‐2 vaccine booster dose in people living with HIV with severe immunosuppression</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description><![CDATA[The aim of this study was to assess the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) vaccines among people living with HIV (PLWH) with severe immunosuppression, after a booster dose. The design was a case–control study nested in a prospective cohort of PLWH. All patients with CD4 cell count <200 cells/mm3 who had received additional dose of messenger RNA (mRNA) COVID‐19 vaccine, after a standard immunization scheme were included. Control group: patients age‐ and sex‐matched, with CD4 ≥ 200 cells/mm3, in the ratio of 2:1. Antibody response to a booster dose (anti‐S levels 33.8 ≥ BAU/mL) and neutralizing activity against SARS‐CoV‐2 B.1, B.1.617.2, and Omicron BA.1, BA.2, and BA.5 strains were assessed after the booster shot. Fifty‐four PLWH were included, 18 with CD4 counts < 200 cells/mm3. Fifty‐one (94%) showed response to a booster dose. Response was less frequent in PLWH with CD4 < 200 cells/mm3 than in those with CD4 counts ≥ 200 cells/mm3 (15 [83%] vs. 36 [100%], p = 0.033). In the multivariate analysis, CD4 counts ≥ 200 cells/mm3 [incidence rate ratio (IRR) = 18.1 (95% confidence interval [CI]: 16.8–19.5), p < 0.001] was associated with a higher probability of showing antibody response. Neutralization activity against SARS‐CoV‐2 B.1, B.1.617, BA.1, and BA.2 strains was significantly inferior among individuals with CD4 counts < 200 cells/mm3. In conclusion, among PLWH with CD4 counts < 200 cells/mm3, the immune response elicited by mRNA additional vaccine dose is reduced.]]></description><subject>Antibodies</subject><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>Antibody Formation</subject><subject>Antibody response</subject><subject>Case-Control Studies</subject><subject>CD4 antigen</subject><subject>CD4 T‐cell counts</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>HIV</subject><subject>HIV Infections</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Immunosuppression</subject><subject>Immunosuppression Therapy</subject><subject>mRNA</subject><subject>Multivariate analysis</subject><subject>Neutralization</subject><subject>Neutralizing</subject><subject>people living with HIV</subject><subject>Prospective Studies</subject><subject>RNA, Messenger</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Sexually transmitted diseases</subject><subject>Statistical analysis</subject><subject>STD</subject><subject>vaccine</subject><subject>Vaccines</subject><subject>Virology</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp10b9u1TAUBnALgeilMPACyBILDGmP_yRxxuoKaFFRpRbuGsXOCfgqsYOd3OoysbDzjH2SuqR0QGKxPfz0nWN9hLxkcMQA-PF22B1xVQB_RFYMqiKroGSPyQqYLLKiYPkBeRbjFgBUxflTciAKpYAVckV-XWI7G2ypw3kKTW9_WPeVNm6y2rd7GjCO3kWkk6dXJ5dXNz9_r_0mnZzuGmOsQ6q9jxMG2vrErKMj-rFH2tvdXdK1nb7R07PN8oi4w5DUMMzOx3kcU3603j0nT7qmj_ji_j4kX96_-7w-zc4vPpytT84zI5TiWSkldFyXrSlQyjx9wAhd5rrlLWdCcGhYg0Z3OXDVGQm5yXkhVSVK6ITutDgkb5bcMfjvM8apHmw02PeNQz_HmpdKCpXGiERf_0O3fg4ubZdUxSqopGRJvV2UCT7GgF09Bjs0YV8zqO-6qVM39Z9ukn11nzjrAdsH-beMBI4XcG173P8_qf74abNE3gJkUJtS</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Corma‐Gómez, Anaïs</creator><creator>Fernández‐Fuertes, Marta</creator><creator>Viñuela, Laura</creator><creator>Domínguez, Carmen</creator><creator>Santos, Marta</creator><creator>Fuentes‐López, Ana</creator><creator>Rojas, Almudena</creator><creator>Fernández‐Pérez, Nieves</creator><creator>Martín‐Carmona, Jessica</creator><creator>Serrano‐Conde, Esther</creator><creator>Real, Luis M.</creator><creator>Mendoza, Joaquín</creator><creator>Macías, Juan</creator><creator>Pineda, Juan A.</creator><creator>García, Federico</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>202303</creationdate><title>Reduced neutralizing antibody response to SARS‐CoV‐2 vaccine booster dose in people living with HIV with severe immunosuppression</title><author>Corma‐Gómez, Anaïs ; Fernández‐Fuertes, Marta ; Viñuela, Laura ; Domínguez, Carmen ; Santos, Marta ; Fuentes‐López, Ana ; Rojas, Almudena ; Fernández‐Pérez, Nieves ; Martín‐Carmona, Jessica ; Serrano‐Conde, Esther ; Real, Luis M. ; Mendoza, Joaquín ; Macías, Juan ; Pineda, Juan A. ; García, Federico</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3882-7440f2b7dc6e445164c3b75bd2d213320a1aecbf5028fc405c526489370f3bfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies</topic><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>Antibody Formation</topic><topic>Antibody response</topic><topic>Case-Control Studies</topic><topic>CD4 antigen</topic><topic>CD4 T‐cell counts</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>HIV</topic><topic>HIV Infections</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Immunosuppression</topic><topic>Immunosuppression Therapy</topic><topic>mRNA</topic><topic>Multivariate analysis</topic><topic>Neutralization</topic><topic>Neutralizing</topic><topic>people living with HIV</topic><topic>Prospective Studies</topic><topic>RNA, Messenger</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Sexually transmitted diseases</topic><topic>Statistical analysis</topic><topic>STD</topic><topic>vaccine</topic><topic>Vaccines</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Corma‐Gómez, Anaïs</creatorcontrib><creatorcontrib>Fernández‐Fuertes, Marta</creatorcontrib><creatorcontrib>Viñuela, Laura</creatorcontrib><creatorcontrib>Domínguez, Carmen</creatorcontrib><creatorcontrib>Santos, Marta</creatorcontrib><creatorcontrib>Fuentes‐López, Ana</creatorcontrib><creatorcontrib>Rojas, Almudena</creatorcontrib><creatorcontrib>Fernández‐Pérez, Nieves</creatorcontrib><creatorcontrib>Martín‐Carmona, Jessica</creatorcontrib><creatorcontrib>Serrano‐Conde, Esther</creatorcontrib><creatorcontrib>Real, Luis M.</creatorcontrib><creatorcontrib>Mendoza, Joaquín</creatorcontrib><creatorcontrib>Macías, Juan</creatorcontrib><creatorcontrib>Pineda, Juan A.</creatorcontrib><creatorcontrib>García, Federico</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Corma‐Gómez, Anaïs</au><au>Fernández‐Fuertes, Marta</au><au>Viñuela, Laura</au><au>Domínguez, Carmen</au><au>Santos, Marta</au><au>Fuentes‐López, Ana</au><au>Rojas, Almudena</au><au>Fernández‐Pérez, Nieves</au><au>Martín‐Carmona, Jessica</au><au>Serrano‐Conde, Esther</au><au>Real, Luis M.</au><au>Mendoza, Joaquín</au><au>Macías, Juan</au><au>Pineda, Juan A.</au><au>García, Federico</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced neutralizing antibody response to SARS‐CoV‐2 vaccine booster dose in people living with HIV with severe immunosuppression</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2023-03</date><risdate>2023</risdate><volume>95</volume><issue>3</issue><spage>e28602</spage><epage>n/a</epage><pages>e28602-n/a</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract><![CDATA[The aim of this study was to assess the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) vaccines among people living with HIV (PLWH) with severe immunosuppression, after a booster dose. The design was a case–control study nested in a prospective cohort of PLWH. All patients with CD4 cell count <200 cells/mm3 who had received additional dose of messenger RNA (mRNA) COVID‐19 vaccine, after a standard immunization scheme were included. Control group: patients age‐ and sex‐matched, with CD4 ≥ 200 cells/mm3, in the ratio of 2:1. Antibody response to a booster dose (anti‐S levels 33.8 ≥ BAU/mL) and neutralizing activity against SARS‐CoV‐2 B.1, B.1.617.2, and Omicron BA.1, BA.2, and BA.5 strains were assessed after the booster shot. Fifty‐four PLWH were included, 18 with CD4 counts < 200 cells/mm3. Fifty‐one (94%) showed response to a booster dose. Response was less frequent in PLWH with CD4 < 200 cells/mm3 than in those with CD4 counts ≥ 200 cells/mm3 (15 [83%] vs. 36 [100%], p = 0.033). In the multivariate analysis, CD4 counts ≥ 200 cells/mm3 [incidence rate ratio (IRR) = 18.1 (95% confidence interval [CI]: 16.8–19.5), p < 0.001] was associated with a higher probability of showing antibody response. Neutralization activity against SARS‐CoV‐2 B.1, B.1.617, BA.1, and BA.2 strains was significantly inferior among individuals with CD4 counts < 200 cells/mm3. In conclusion, among PLWH with CD4 counts < 200 cells/mm3, the immune response elicited by mRNA additional vaccine dose is reduced.]]></abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36880164</pmid><doi>10.1002/jmv.28602</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2023-03, Vol.95 (3), p.e28602-n/a |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2784387443 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antibodies Antibodies, Neutralizing Antibodies, Viral Antibody Formation Antibody response Case-Control Studies CD4 antigen CD4 T‐cell counts Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 Vaccines HIV HIV Infections Human immunodeficiency virus Humans Immune response Immune system Immunization Immunogenicity Immunosuppression Immunosuppression Therapy mRNA Multivariate analysis Neutralization Neutralizing people living with HIV Prospective Studies RNA, Messenger SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Sexually transmitted diseases Statistical analysis STD vaccine Vaccines Virology |
| title | Reduced neutralizing antibody response to SARS‐CoV‐2 vaccine booster dose in people living with HIV with severe immunosuppression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T22%3A02%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20neutralizing%20antibody%20response%20to%20SARS%E2%80%90CoV%E2%80%902%20vaccine%20booster%20dose%20in%20people%20living%20with%20HIV%20with%20severe%20immunosuppression&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Corma%E2%80%90G%C3%B3mez,%20Ana%C3%AFs&rft.date=2023-03&rft.volume=95&rft.issue=3&rft.spage=e28602&rft.epage=n/a&rft.pages=e28602-n/a&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.28602&rft_dat=%3Cproquest_cross%3E2791909441%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2791909441&rft_id=info:pmid/36880164&rfr_iscdi=true |